Literature DB >> 27498863

NAMPT-Mediated NAD(+) Biosynthesis in Adipocytes Regulates Adipose Tissue Function and Multi-organ Insulin Sensitivity in Mice.

Kelly L Stromsdorfer1, Shintaro Yamaguchi1, Myeong Jin Yoon2, Anna C Moseley1, Michael P Franczyk1, Shannon C Kelly1, Nathan Qi3, Shin-Ichiro Imai2, Jun Yoshino4.   

Abstract

Obesity is associated with adipose tissue dysfunction and multi-organ insulin resistance. However, the mechanisms of such obesity-associated systemic metabolic complications are not clear. Here, we characterized mice with adipocyte-specific deletion of nicotinamide phosphoribosyltransferase (NAMPT), a rate-limiting NAD(+) biosynthetic enzyme known to decrease in adipose tissue of obese and aged rodents and people. We found that adipocyte-specific Nampt knockout mice had severe insulin resistance in adipose tissue, liver, and skeletal muscle and adipose tissue dysfunction, manifested by increased plasma free fatty acid concentrations and decreased plasma concentrations of a major insulin-sensitizing adipokine, adiponectin. Loss of Nampt increased phosphorylation of CDK5 and PPARγ (serine-273) and decreased gene expression of obesity-linked phosphorylated PPARγ targets in adipose tissue. These deleterious alterations were normalized by administering rosiglitazone or a key NAD(+) intermediate, nicotinamide mononucleotide (NMN). Collectively, our results provide important mechanistic and therapeutic insights into obesity-associated systemic metabolic derangements, particularly multi-organ insulin resistance.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NAD(+); NAMPT; PPARγ; adipocyte; insulin resistance; obesity

Mesh:

Substances:

Year:  2016        PMID: 27498863      PMCID: PMC5094180          DOI: 10.1016/j.celrep.2016.07.027

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  35 in total

Review 1.  The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing.

Authors:  S Imai; J Yoshino
Journal:  Diabetes Obes Metab       Date:  2013-09       Impact factor: 6.577

2.  Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice.

Authors:  Jun Yoshino; Kathryn F Mills; Myeong Jin Yoon; Shin-ichiro Imai
Journal:  Cell Metab       Date:  2011-10-05       Impact factor: 27.287

3.  OP9 mouse stromal cells rapidly differentiate into adipocytes: characterization of a useful new model of adipogenesis.

Authors:  Nathan E Wolins; Benjamin K Quaynor; James R Skinner; Anatoly Tzekov; Changwon Park; Kyunghee Choi; Perry E Bickel
Journal:  J Lipid Res       Date:  2005-11-30       Impact factor: 5.922

4.  Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.

Authors:  Vijayalakshmi Varma; Aiwei Yao-Borengasser; Neda Rasouli; Angela M Bodles; Bounleut Phanavanh; Mi-Jeong Lee; Tasha Starks; Leslie M Kern; Horace J Spencer; Robert E McGehee; Susan K Fried; Philip A Kern
Journal:  J Clin Endocrinol Metab       Date:  2006-11-07       Impact factor: 5.958

Review 5.  Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.

Authors:  Adilson Guilherme; Joseph V Virbasius; Vishwajeet Puri; Michael P Czech
Journal:  Nat Rev Mol Cell Biol       Date:  2008-05       Impact factor: 94.444

6.  A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.

Authors:  Sun-Sil Choi; Eun Sun Kim; Minseob Koh; Soo-Jin Lee; Donghyun Lim; Yong Ryoul Yang; Hyun-Jun Jang; Kyung-Ah Seo; Sang-Hyun Min; In Hee Lee; Seung Bum Park; Pann-Ghill Suh; Jang Hyun Choi
Journal:  J Biol Chem       Date:  2014-08-06       Impact factor: 5.157

7.  PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect.

Authors:  Sorin Tunaru; Jukka Kero; Annette Schaub; Christian Wufka; Andree Blaukat; Klaus Pfeffer; Stefan Offermanns
Journal:  Nat Med       Date:  2003-02-03       Impact factor: 53.440

8.  Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.

Authors:  Jang Hyun Choi; Alexander S Banks; Theodore M Kamenecka; Scott A Busby; Michael J Chalmers; Naresh Kumar; Dana S Kuruvilla; Youseung Shin; Yuanjun He; John B Bruning; David P Marciano; Michael D Cameron; Dina Laznik; Michael J Jurczak; Stephan C Schürer; Dušica Vidović; Gerald I Shulman; Bruce M Spiegelman; Patrick R Griffin
Journal:  Nature       Date:  2011-09-04       Impact factor: 49.962

9.  Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis.

Authors:  Kathryn Moynihan Ramsey; Jun Yoshino; Cynthia S Brace; Dana Abrassart; Yumiko Kobayashi; Biliana Marcheva; Hee-Kyung Hong; Jason L Chong; Ethan D Buhr; Choogon Lee; Joseph S Takahashi; Shin-Ichiro Imai; Joseph Bass
Journal:  Science       Date:  2009-03-19       Impact factor: 47.728

10.  Adipocyte SIRT1 knockout promotes PPARγ activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity.

Authors:  Rafael Mayoral; Olivia Osborn; Joanne McNelis; Andrew M Johnson; Da Young Oh; Cristina Llorente Izquierdo; Heekyung Chung; Pingping Li; Paqui G Traves; Gautam Bandyopadhyay; Ariane R Pessentheiner; Jachelle M Ofrecio; Joshua R Cook; Li Qiang; Domenico Accili; Jerrold M Olefsky
Journal:  Mol Metab       Date:  2015-03-05       Impact factor: 8.568

View more
  62 in total

Review 1.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

Review 2.  NAD+ metabolism and its roles in cellular processes during ageing.

Authors:  Anthony J Covarrubias; Rosalba Perrone; Alessia Grozio; Eric Verdin
Journal:  Nat Rev Mol Cell Biol       Date:  2020-12-22       Impact factor: 94.444

3.  The Emergence of the Nicotinamide Riboside Kinases in the regulation of NAD+ Metabolism.

Authors:  Rachel S Fletcher; Gareth Lavery
Journal:  J Mol Endocrinol       Date:  2018-05-30       Impact factor: 5.098

4.  Adipose tissue NAD+ biosynthesis is required for regulating adaptive thermogenesis and whole-body energy homeostasis in mice.

Authors:  Shintaro Yamaguchi; Michael P Franczyk; Maria Chondronikola; Nathan Qi; Subhadra C Gunawardana; Kelly L Stromsdorfer; Lane C Porter; David F Wozniak; Yo Sasaki; Nicholas Rensing; Michael Wong; David W Piston; Samuel Klein; Jun Yoshino
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-06       Impact factor: 11.205

5.  NAD(H) in mitochondrial energy transduction: implications for health and disease.

Authors:  Matthew A Walker; Rong Tian
Journal:  Curr Opin Physiol       Date:  2018-04-11

6.  Dysregulation of NAD+ Metabolism Induces a Schwann Cell Dedifferentiation Program.

Authors:  Yo Sasaki; Amber R Hackett; Sungsu Kim; Amy Strickland; Jeffrey Milbrandt
Journal:  J Neurosci       Date:  2018-06-19       Impact factor: 6.167

Review 7.  Adipose tissue NAD+ biology in obesity and insulin resistance: From mechanism to therapy.

Authors:  Shintaro Yamaguchi; Jun Yoshino
Journal:  Bioessays       Date:  2017-03-15       Impact factor: 4.345

Review 8.  NAD+ and sirtuins in retinal degenerative diseases: A look at future therapies.

Authors:  Jonathan B Lin; Rajendra S Apte
Journal:  Prog Retin Eye Res       Date:  2018-06-12       Impact factor: 21.198

Review 9.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

10.  Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.

Authors:  Harshini Neelakantan; Virginia Vance; Michael D Wetzel; Hua-Yu Leo Wang; Stanton F McHardy; Celeste C Finnerty; Jonathan D Hommel; Stanley J Watowich
Journal:  Biochem Pharmacol       Date:  2017-11-15       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.